Cerdulatinib (PRT062070, PRT2070) is a synthetic small molecule and specialty chemical primarily utilized as a research reagent in the field of oncology. It serves as a dual inhibitor of SYK and JAK kinases, key enzymes involved in signaling pathways that promote cancer cell growth and survival. This compound is particularly relevant for studying hematologic malignancies, including chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and other B-cell malignancies. By blocking these kinases, cerdulatinib inhibits cancer cell proliferation and induces apoptosis in preclinical models. It is under investigation for its potential to overcome resistance to other therapies, providing a promising research tool for relapsed or refractory diseases. Note: This product is intended for laboratory research use only and not for human therapeutic applications. Its oral bioavailability in pharmacological studies supports convenient dosing models, potentially enhancing research on patient compliance and treatment outcomes.